02 Feb 2022 by admin in UncategorizedComments Syros Receives FDA Orphan Drug Designation for Tamibarotene for the Treatment of MDS
01 Feb 2022 by admin in UncategorizedComments Design Therapeutics Appoints Drug Development Expert, Jae Kim, M.D., as Chief Medical Officer
10 Jan 2022 by admin in UncategorizedComments Syros Announces Clinical Updates and 2022 Goals to Support its Advancement to a Fully Integrated Biopharmaceutical Company
10 Jan 2022 by admin in UncategorizedComments BioNTech and Crescendo Biologics announce global collaboration to develop multi-specific precision immunotherapies
12 Dec 2021 by admin in UncategorizedComments NextCure and Collaborators Provide Data on Targets in Development at American Society of Hematology Annual Meeting
